Department of Interventional Radiology, The Cancer Hospital of Harbin Medical University, Harbin, 150040, PR China.
Department of Medical Oncology, The Cancer Hospital of Harbin Medical University, Harbin, 150040, PR China.
Future Oncol. 2018 May;14(12):1165-1176. doi: 10.2217/fon-2017-0354. Epub 2018 Jan 16.
The purpose of this study was to evaluate the efficacy and safety of the endovascular implantation of I seed under ultrasound and x-ray guidance combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
PATIENTS & METHODS: The study included 134 pathologically proven or clinically confirmed primary HCC patients with PVTT in our hospital from January 2013 to June 2015.
RESULTS & CONCLUSION: Compared with the TACE treatment alone, the combination therapy of I seed implantation with TACE significantly prolonged the median survival time and improved the 6-, 12- and 18-month survival rates for HCC patients with PVTT. In addition, the type III PVTT and tumor size were independent predictors for poor prognosis of HCC patients with PVTT.
本研究旨在评估超声和 X 射线引导下经皮穿刺植入放射性碘 125 粒子联合肝动脉化疗栓塞（TACE）治疗肝癌合并门静脉癌栓（PVTT）患者的疗效和安全性。
本研究纳入了 2013 年 1 月至 2015 年 6 月在我院经病理或临床证实的 134 例原发性肝癌合并 PVTT 患者。
与单纯 TACE 治疗相比，放射性碘 125 粒子植入联合 TACE 治疗显著延长了肝癌合并 PVTT 患者的中位生存时间，并提高了患者 6、12 和 18 个月的生存率。此外，Ⅲ型 PVTT 和肿瘤大小是影响肝癌合并 PVTT 患者预后的独立预测因素。
